Picture of Pulmonx logo

LUNG Pulmonx Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousSmall CapNeutral

Momentum

Relative Strength (%)
1m-38.27%
3m-33.79%
6m-25.97%
1yr-38.44%
Volume Change (%)
10d/3m+48.4%
Price vs... (%)
52w High-37.92%
50d MA-22.26%
200d MA-19.33%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-40.06%
Return on Equity-44.68%
Operating Margin-90.19%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Pulmonx EPS forecast chart

Profile Summary

Pulmonx Corporation is a commercial-stage medical technology company. The Company provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. Its solutions, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System) and the StratX Lung Analysis Platform (StratX Platform), is designed to treat severe emphysema patients. The StratX Platform is a cloud-based quantitative CT analysis service that offers physicians with a report that is designed for its solution, which includes information on emphysema destruction, fissure completeness and lobar volume to help identify target lobes for treatment with Zephyr Valves. The Chartis System is a balloon catheter and console system with flow and pressure sensors designed to assess the presence of collateral ventilation and has been validated in multiple randomized controlled clinical trials.

Directors

Last Annual
December 31st, 2023
Last Interim
December 31st, 2023
Incorporated
December 4th, 2013
Public Since
October 1st, 2020
No. of Shareholders
136
No. of Employees
279
Sector
Healthcare Equipment & Supplies
Industry
Healthcare
Exchange
us flag iconNASDAQ Global Select Market
Shares in Issue
38,537,356

LUNG Share Price Performance

Upcoming Events for LUNG

Q1 2024 Pulmonx Corp Earnings Release

Pulmonx Corp Annual Shareholders Meeting

Q2 2024 Pulmonx Corp Earnings Release

Similar to LUNG

Picture of 10X Genomics logo

10X Genomics

us flag iconNASDAQ Global Select Market

Picture of Accuray logo

Accuray

us flag iconNASDAQ Global Select Market

Picture of Akoya Biosciences logo

Akoya Biosciences

us flag iconNASDAQ Global Select Market

Picture of Align Technology logo

Align Technology

us flag iconNASDAQ Global Select Market

Picture of Alphatec Holdings logo

Alphatec Holdings

us flag iconNASDAQ Global Select Market

FAQ